CONTEXT: Estrogen receptor and progesterone receptor status is assessed on all newly diagnosed, invasive breast carcinomas and in recurrences to determine patient eligibility for hormonal therapy, but 10% to 20% of estrogen receptor and progesterone receptor test results are discordant when tested in multiple laboratories. OBJECTIVE: To define the analytic (technical) validation requirements for estrogen receptor and progesterone receptor immunohistochemistry assays used to select patients for hormonal therapy. DATA SOURCES: Literature review and expert consensus. CONCLUSIONS: A standardized process for initial test validation is described. We believe adoption of this process will improve the accuracy of hormone-receptor testing, reduce interlaboratory variation, and minimize false-positive and false-negative results. Required ongoing assay assessment procedures are also described.
CONTEXT: Estrogen receptor and progesterone receptor status is assessed on all newly diagnosed, invasive breast carcinomas and in recurrences to determine patient eligibility for hormonal therapy, but 10% to 20% of estrogen receptor and progesterone receptor test results are discordant when tested in multiple laboratories. OBJECTIVE: To define the analytic (technical) validation requirements for estrogen receptor and progesterone receptor immunohistochemistry assays used to select patients for hormonal therapy. DATA SOURCES: Literature review and expert consensus. CONCLUSIONS: A standardized process for initial test validation is described. We believe adoption of this process will improve the accuracy of hormone-receptor testing, reduce interlaboratory variation, and minimize false-positive and false-negative results. Required ongoing assay assessment procedures are also described.
Authors: Rajesh C Dash; James A Robb; David L Booker; Wen-Chi Foo; David L Witte; Lynn Bry Journal: Arch Pathol Lab Med Date: 2012-06 Impact factor: 5.534
Authors: M Elizabeth H Hammond; Daniel F Hayes; Mitch Dowsett; D Craig Allred; Karen L Hagerty; Sunil Badve; Patrick L Fitzgibbons; Glenn Francis; Neil S Goldstein; Malcolm Hayes; David G Hicks; Susan Lester; Richard Love; Pamela B Mangu; Lisa McShane; Keith Miller; C Kent Osborne; Soonmyung Paik; Jane Perlmutter; Anthony Rhodes; Hironobu Sasano; Jared N Schwartz; Fred C G Sweep; Sheila Taube; Emina Emilia Torlakovic; Paul Valenstein; Giuseppe Viale; Daniel Visscher; Thomas Wheeler; R Bruce Williams; James L Wittliff; Antonio C Wolff Journal: Arch Pathol Lab Med Date: 2010-06 Impact factor: 5.534
Authors: Adi Pais; Chidambaram Gunanathan; Raanan Margalit; Inbal Eti Biton; Ady Yosepovich; David Milstein; Hadassa Degani Journal: Cancer Res Date: 2011-10-31 Impact factor: 12.701
Authors: Marilyn M Bui; Michael W Riben; Kimberly H Allison; Elizabeth Chlipala; Carol Colasacco; Andrea G Kahn; Christina Lacchetti; Anant Madabhushi; Liron Pantanowitz; Mohamed E Salama; Rachel L Stewart; Nicole E Thomas; John E Tomaszewski; M Elizabeth Hammond Journal: Arch Pathol Lab Med Date: 2019-01-15 Impact factor: 5.534